Cancer Registry Zurich, Zug, Schaffhausen and Schwyz, Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Cancer Med. 2023 Sep;12(17):18165-18175. doi: 10.1002/cam4.6392. Epub 2023 Aug 1.
Survival trends help to evaluate the progress made to reduce the burden of cancer. The aim was to estimate the trends in 5-year relative survival of patients diagnosed with breast, prostate, lung, colorectal cancer and skin melanoma in the time periods 1980-1989, 1990-1999, 2000-2009 and 2010-2015 in the Canton of Zurich, Switzerland. Furthermore, we investigated relative survival differences by TNM stage and age group.
Data from the Cancer Registry of Zurich was used from 1980 to and including 2015, including incident cases of breast (N = 26,060), prostate (N= 23,858), colorectal (N= 19,305), lung cancer (N= 16,858) and skin melanoma (N= 9780) with follow-up until 31 December 2020. The cohort approach was used to estimate 5-year relative survival.
The 5-year relative survival increased significantly between 1980 and 1989, and 2010 and2015: from 0.70 to 0.89 for breast, from 0.60 to 0.92 for prostate, from 0.09 to 0.23 (men) and from 0.10 to 0.27 (women) for lung, from 0.46 to 0.66 (men) and from 0.48 to 0.68 (women) for colorectal cancer, and from 0.74 to 0.94 (men) and from 0.86 to 0.96 (women) for skin melanoma. Survival for stage IV tumors was considerably lower compared to lower-staged tumors for all cancer types. Furthermore, relative survival was similar for the age groups <80 years but lower for patients aged 80 years and older.
The observed increasing trends in survival are encouraging and likely reflect raised awareness around cancer, improved diagnostic methods, and improved treatments. The fact that stage I tumor patients have generally high relative survival reflects the efforts made regarding early detection.
生存趋势有助于评估减轻癌症负担方面取得的进展。本研究旨在评估瑞士苏黎世州在 1980-1989 年、1990-1999 年、2000-2009 年和 2010-2015 年期间诊断为乳腺癌、前列腺癌、肺癌、结直肠癌和皮肤黑色素瘤的患者的 5 年相对生存率趋势。此外,我们还研究了不同 TNM 分期和年龄组的相对生存率差异。
本研究使用了苏黎世癌症登记处的数据,时间范围为 1980 年至 2015 年,包括 26060 例乳腺癌、23858 例前列腺癌、19305 例结直肠癌、16858 例肺癌和 9780 例皮肤黑色素瘤患者的发病数据,并随访至 2020 年 12 月 31 日。采用队列研究方法估计 5 年相对生存率。
1980 年至 1989 年和 2010 年至 2015 年期间,5 年相对生存率显著提高:乳腺癌从 0.70 提高至 0.89,前列腺癌从 0.60 提高至 0.92,肺癌(男性)从 0.09 提高至 0.23,肺癌(女性)从 0.10 提高至 0.27,结直肠癌(男性)从 0.46 提高至 0.66,结直肠癌(女性)从 0.48 提高至 0.68,皮肤黑色素瘤(男性)从 0.74 提高至 0.94,皮肤黑色素瘤(女性)从 0.86 提高至 0.96。所有癌症类型中,IV 期肿瘤的生存率明显低于低分期肿瘤。此外,<80 岁年龄组的相对生存率相似,但 80 岁及以上患者的生存率较低。
观察到的生存率上升趋势令人鼓舞,可能反映了癌症意识的提高、诊断方法的改进和治疗的改善。I 期肿瘤患者的相对生存率普遍较高,这反映了早期发现方面的努力。